RTP Mobile Logo
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia — Part 3 of a 5-Part Series (Webinar Audio Proceedings)
Released January 2022

Featuring perspectives from Dr Naval Daver. Published January 26, 2022. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia.

    LEARNING OBJECTIVES

    • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
    • Appreciate the FDA approval of venetoclax in combination with azacitidine or decitabine or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
    • Review Phase III data documenting the efficacy of CC-486 (oral azacitidine) as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and consider how this novel strategy can be applied in clinical management.
    • Reflect on available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
    • Develop an understanding of the mechanisms of action of, published data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation.
    • Assess the FDA-approved indications for CPX-351 for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
    • Recall promising agents and investigational strategies under evaluation for AML, and counsel appropriately selected patients regarding clinical trial enrollment.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Naval Daver, MD
    Director, Leukemia Research Alliance Program
    Associate Professor
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Hanmi Pharmaceutical, ImmunoGen Inc, NovImmune SA, Pfizer Inc, Servier Pharmaceuticals LLC, Trillium Therapeutics Inc, Trovagene.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Servier Pharmaceuticals LLC.

    Release date: January 2022
    Expiration date: January 2023

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):